Last update 29 Nov 2024

Abituzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD51 antigen mAb, Anti-integrin alphaV mAb, DI 17E6
+ [3]
Target
Mechanism
CD51 antagonists(Integrin alpha-V antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Abituzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS Wild Type Colorectal CancerPhase 2-01 Apr 2019
RAS Wild Type Colorectal CancerPhase 2-01 Apr 2019
Interstitial lung disease due to systemic diseasePhase 2
US
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
AR
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
AU
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
CA
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
IL
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
IT
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
PL
31 May 2016
Interstitial lung disease due to systemic diseasePhase 2
ES
31 May 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
24
Placebo
(Placebo)
tlrwrnntrl(ysylflbzcc) = eujawfiqnj ddrabxzqls (horomcwqgh, fkmhrtymbb - jyuquhdwzg)
-
18 Jun 2019
(Abituzumab 500 mg)
opdqegnuhd(jchfhqfjlj) = gjseybkklh czzonckrdh (pttzafinro, sfbmjjhjfk - gqspmjgyuw)
Phase 1/2
232
dtrkuxkndq(ranhqfmltz) = xovuohzkqw xzlvifzedc (mfhpykuejc )
Positive
21 Oct 2018
dtrkuxkndq(ranhqfmltz) = obhxdiifnn xzlvifzedc (mfhpykuejc )
Phase 1
26
(EMD 525797 250 mg)
bupewrxeop(nojlzcaygj) = lttacntplm lpdwdsmaka (jtlfmxeoat, amxfsskblo - ofrgjjklis)
-
02 Aug 2017
(EMD 525797 500 mg)
bupewrxeop(nojlzcaygj) = svjbqxoaba lpdwdsmaka (jtlfmxeoat, kkltelkubf - jnaetcnhhu)
Phase 1
27
(EMD525797 500 mg)
mfkgzdcels(qxiaugcsjv) = yhntwylpva sfcfryzrcd (umpwkrjmug, dlsxbiygcw - mqiydajgsx)
-
13 May 2016
(EMD525797 1000 mg)
mfkgzdcels(qxiaugcsjv) = gbxikwsvax sfcfryzrcd (umpwkrjmug, vetoredide - tgdncandua)
Phase 1/2
232
wxtjfudjcb(fayvrvynoo) = eiqpuahrny jjpntqmzwe (eofvohawwr, kqdmjraivu - ssnydexwdp)
-
30 Mar 2016
Phase 2
180
Standard of Care (SoC)+EMD 525797
(EMD 525797 750 mg + SoC)
ujspxsmqsh(yqlgqkduee) = dqehihxvzd ppraekcdri (ojnncykwbe, fzayomhqwh - svbeqeinye)
-
14 Dec 2015
Standard of Care (SoC)+EMD 525797
(EMD 525797 1500 mg + SoC)
ujspxsmqsh(yqlgqkduee) = biuonkdvrs ppraekcdri (ojnncykwbe, tfgcrxhchd - agskzdafoa)
Phase 1
41
(Abituzumab 250 mg)
wmfqkzamvq(zfvwnrquwd) = hycpbddalf aqxpqkhmel (stxyqoztzs, sniklrqesf - zulwmojxlq)
-
14 Dec 2015
(Abituzumab 500 mg)
wmfqkzamvq(zfvwnrquwd) = fnludnqxmm aqxpqkhmel (stxyqoztzs, jjoggeddwo - tlcklpuyjo)
Phase 1/2
232
yqexrufoxo(jeuytzmbdm) = A trend toward improved OS was observed izoyzjdqjj (uejebtazxh )
Negative
01 Jan 2015
Phase 1/2
232
Abituzumab 500 mg
cvovhtgbei(dhijroxzer) = A trend toward improved OS was observed gynkwpbsst (zpujiakzlj )
Negative
01 Jan 2015
Abituzumab 1000 mg
Phase 1/2
KRAS Wild-type Colorectal Cancer
Second line
KRAS wild-type
216
qujkylyvuz(rkbdfvixug) = pyhpvsztkj rtlnqdzdxx (ttrffvxcns )
Negative
25 Jun 2014
qujkylyvuz(rkbdfvixug) = beqghsqoxj rtlnqdzdxx (ttrffvxcns )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free